Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats.

Translational Psychiatry
Daniel VallöfElisabet Jerlhag

Abstract

Given the limited efficacy of available pharmacotherapies for treatment of alcohol use disorder (AUD), the need for new medications is substantial. Preclinical studies have shown that acute administration of glucagon-like peptide-1 receptor (GLP-1R) agonists inhibits various ethanol-related behaviours, indicating this system as a potential target for AUD. However, the effects of long-term systemic treatment of GLP-1R agonists on ethanol intake in male and female rodents are to date unknown. Therefore, we investigated the effects of 9 or 5 weeks of once weekly administration of dulaglutide, a long-acting GLP-1R agonist, on ethanol intake in male and female rats. The ethanol intake during treatment discontinuation was also monitored. In an initial attempt to identify preliminary underlying mechanisms, the effects of 9 weeks of once weekly dulaglutide treatment on monoaminergic signalling in reward-related areas were explored in both sexes. We found that 9 or 5 weeks of once weekly dulaglutide treatment reduced ethanol intake and preference in male and female rats. Following discontinuation of dulaglutide treatment, the decrease in ethanol consumption was prolonged in males, but not females. We demonstrated that 9 weeks of dulaglu...Continue Reading

References

May 1, 1992·Trends in Pharmacological Sciences·G F Koob
Mar 21, 1998·The Journal of Clinical Investigation·A FlintJ J Holst
Dec 20, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G F Koob, M Le Moal
Apr 13, 2007·Alcoholism, Clinical and Experimental Research·Karmen K YoderEvan D Morris
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Aug 2, 2008·Alcoholism, Clinical and Experimental Research·Jeffrey A SimmsSelena E Bartlett
Dec 24, 2009·Diabetes Care·Guillermo E UmpierrezAbbas E Kitabchi
May 19, 2010·Addiction Biology·Emil EgeciogluSuzanne L Dickson
May 19, 2010·Molecular Psychiatry·V A RamchandaniM Heilig
May 27, 2010·Diabetes/metabolism Research and Reviews·Wolfgang GlaesnerTom Bumol
Dec 12, 2012·Psychoneuroendocrinology·Emil EgeciogluElisabet Jerlhag
Dec 15, 2012·The Journal of Comparative Neurology·Guibao GuJoseph S Heilig
Jun 20, 2014·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Amber L Alhadeff, Harvey J Grill
Sep 10, 2014·The Journal of Clinical Investigation·Anna SecherLotte Bjerre Knudsen
Sep 1, 2016·Alcoholism, Clinical and Experimental Research·Gunnar SørensenMorgane Thomsen
Aug 6, 2017·Pharmacology, Biochemistry, and Behavior·Morgane ThomsenAnna Molander
Sep 19, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David J ReinerMatthew R Hayes
Oct 7, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roy A Wise, Ross A McDevitt
Dec 2, 2017·Pharmacology & Therapeutics·Mohammed AkbarAntonio Noronha
Mar 6, 2018·Current Obesity Reports·Gitanjali Srivastava, Caroline Apovian
Nov 2, 2018·Psychopharmacology·Morgane ThomsenAnders Fink-Jensen
Feb 11, 2019·Physiology & Behavior·Mehdi FarokhniaLorenzo Leggio
Oct 4, 2019·Science Advances·K WitkiewitzL Leggio

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies

Software Mentioned

ARRIVE
Dionex Chromeleon

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Australian Prescriber
Alessandra Sandrini
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Tara GurungNorman Waugh
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Angela M Thompson, Jennifer M Trujillo
© 2021 Meta ULC. All rights reserved